We have committed to do all of the science and drug discovery and work to get to proof of concept, which is around Phase 2A. For dengue and TB, we will pay for FDA trials.
At Index Ventures, we have modelled the early stage development process (up to proof of clinical concept) on the presumption that the majority of the risk in a discovery programme is not only unknown but it also unknowable (ahead of testing in man).